You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR TRABECTEDIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TRABECTEDIN

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002904 ↗	Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 1	1996-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.
NCT00003939 ↗	Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1969-12-31	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
NCT00005625 ↗	Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma	Completed	National Cancer Institute (NCI)	Phase 2	1999-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00005625 ↗	Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1999-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have previously treated metastatic osteosarcoma.
NCT00017030 ↗	Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma	Completed	National Cancer Institute (NCI)	Phase 2	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
NCT00017030 ↗	Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have unresectable advanced or metastatic soft tissue sarcoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TRABECTEDIN

Condition Name

Chart
Table

Condition Name for TRABECTEDIN
Intervention	Trials
Sarcoma	13
Soft Tissue Sarcoma	12
Leiomyosarcoma	8
Ovarian Cancer	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TRABECTEDIN
Intervention	Trials
Sarcoma	41
Leiomyosarcoma	17
Ovarian Neoplasms	15
Liposarcoma	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TRABECTEDIN

Trials by Country

Map
Table

Trials by Country for TRABECTEDIN
Location	Trials
United States	259
Italy	143
Spain	37
Germany	31
France	26
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TRABECTEDIN
Location	Trials
California	16
Pennsylvania	14
Massachusetts	14
New York	14
Washington	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TRABECTEDIN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TRABECTEDIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	15
Phase 2/Phase 3	3
[disabled in preview]	68
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TRABECTEDIN
Clinical Trial Phase	Trials
Completed	50
Recruiting	17
Active, not recruiting	9
[disabled in preview]	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRABECTEDIN

Sponsor Name

Chart
Table

Sponsor Name for TRABECTEDIN
Sponsor	Trials
PharmaMar	35
National Cancer Institute (NCI)	13
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	12
[disabled in preview]	23
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TRABECTEDIN
Sponsor	Trials
Other	97
Industry	76
NIH	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.